Clinical trials: Previously Treated Non Small Cell Lung Cancer
Lung Cancer
Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy such as docetaxel use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00030641
- Testing
- oblimersen sodium, docetaxel
- Where
- 44 sites in United States, Canada and 1 more
- Sponsor
- Genta Incorporated
NSCLC
QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC
The goal of this clinical trial is to evaluate QL1706 plus bevacizumab with or without chemotherapy in patients with PD-L1-negative, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) previously…
- Trial name
- NCT07134413
- Testing
- QL1706 plus bevacizumab with or without chemotherapy
- Volunteers
- 77 people
- Sponsor
- Guangdong Association of Clinical Trials
Non-Small-Cell Lung Cancer
Phase II Trial of Continuation Therapy in Advanced NSCLC
This is a single-arm phase II study of continuation immunotherapy with pembrolizumab following initial benefit (CR, PR, or SD ≥ 3 months) with a PD-1 or PD-L1 inhibitor.
- Trial name
- NCT03083808
- Testing
- Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Greg Durm, MD
Lung Cancer, Lung Cancer Metastatic
Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 study evaluating STRO-002 in subjects with previously treated advanced or metastatic non-small cell lung cancer expressing FOLR1
- Conditions
- Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Nonsmall Cell, Lung Cancer Non-Small Cell Stage IIIB
- Trial name
- NCT06555263
- Testing
- Luveltamab tazevibulin
- Where
- 7 sites in United States
- Sponsor
- Sutro Biopharma, Inc.
Metastatic Non-small Cell Lung Cancer (NSCLC), Metastatic Cutaneous Melanoma
Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade
This study will evaluate efficacy and safety of anti-PD-1/PD-L1 antibodies combined with bevacizumab and metronomic cyclophosphamide in patients with metastatic non-small cell lung cancer (NSCLC) and cutaneous melanoma previously…
- Trial name
- reICB (NCT07130032)
- Testing
- reICB regimen (NSCLC), reICB regimen (melanoma)
- Where
- Russia
- Volunteers
- 90 people
- Sponsor
- EuroCityClinic LLC
Lung Cancer
Temozolomide in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have stage IIIB…
- Trial name
- NCT00005037
- Testing
- temozolomide
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Fox Chase Cancer Center
Non Small-cell Lung Cancer, Locally Advanced Unresectable NSCLC
Expanded Access of Sotorasib
The primary objective of this study is to provide expanded access to and characterize the safety profile of Sotorasib in participants with previously treated locally advanced/unresectable/metastatic non small-cell lung cancer…
- Conditions
- Non Small-cell Lung Cancer, Locally Advanced Unresectable NSCLC, Locally Advanced Metastatic NSCLC
- Trial name
- NCT04667234
- Testing
- AMG 510
- Where
- 55 sites in United States, Argentina and 4 more
- Sponsor
- Amgen
Carcinoma, Non-Small-Cell Lung, EGFR Mutant Advanced Non-Small Cell Lung Cancer
A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients
This is a Phase 1/2, open-label study designed to investigate the safety, tolerability, PK, and anti-tumor activity of the study treatment in the treatment of patients with EGFR mutant NSCLC, who progressed following prior…
- Trial name
- NCT06186076
- Testing
- TRX-221
- Where
- 6 sites in South Korea
- Volunteers
- 19 people
- Sponsor
- Therapex Co., Ltd
Non-small Cell Lung Cancer (NSCLC)
A Study of Real-world Treatment Patterns and Outcomes in Chinese Advanced NSCLC Patients Who Previously Received at Least 2 Line Treatments
This study will retrospectively collect data of patients with advanced non-small cell lung cancer who have received at least 2 line treatment to investigate treatment patterns, relevant outcomes, and biomarkers detection patterns…
- Trial name
- RECAP (NCT06617390)
- Testing
- No drug
- Where
- 6 sites in China
- Volunteers
- 1,041 people
- Sponsor
- Daiichi Sankyo
EGFR-TKI Resistant Mutation, Nonsmall Cell Lung Cancer
Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M
The study aims to investigate the efficacy and safety of AZD9291 in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI.
- Conditions
- EGFR-TKI Resistant Mutation, Nonsmall Cell Lung Cancer, AZD9291, Brain Metastases
- Trial name
- NCT02972333
- Testing
- AZD9291 80mg oral each day, Radiation therapy
- Volunteers
- 150 people
- Sponsor
- Shandong Cancer Hospital and Institute
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage…
- Trial name
- NCT06616584
- Testing
- Biospecimen Collection, Cemiplimab, Computed Tomography
- Where
- 413 sites in United States
- Volunteers
- 378 people
- Sponsor
- SWOG Cancer Research Network
Non-Small Cell Lung Cancer
Safety and Pharmacokinetics of Jin Fu Kang in Comb w/Docetaxel for Patients w/Non-Small Cell Lung Cancer
Researchers from Memorial Sloan-Kettering Cancer Center are conducting a research study on a Chinese herbal medicine known as "Jin Fu Kang". We want to see if this can help patients with advanced lung cancer.
- Trial name
- NCT00260026
- Testing
- Docetaxel, Jin Fu Kang
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Carcinoma, Non-Small-Cell Lung
OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer
This study determines tumor response rate, time to tumor progression and survival rate at 1 year produced by OSI-774 in previously treated African American patients with nonsmall cell lung cancer.
- Trial name
- NCT00230126
- Testing
- erlotinib
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Adult Solid Neoplasm, Bladder Carcinoma
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
This phase I trial studies the side effects of vaccine therapy and pembrolizumab in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment, that…
- Conditions
- Adult Solid Neoplasm, Bladder Carcinoma, Colon Carcinoma, Estrogen Receptor Negative
- Trial name
- NCT02432963
- Testing
- Laboratory Biomarker Analysis, Modified Vaccinia Virus Ankara Vaccine Expressing p53, Pembrolizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- City of Hope Medical Center
Carcinoma, Non-Small-Cell Lung
MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer Patients
This is a phase II open-label randomized clinical trial of MK-3475 (Pembrolizumab) on previously treated non-small cell lung cancer (NSCLC) patients .
- Trial name
- NCT02574598
- Testing
- MK-3475, Docetaxel
- Where
- Mexico
- Volunteers
- 78 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Non-Small Cell Lung Cancer, c-MET
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung.
- Trial name
- NCT06568939
- Testing
- Telisotuzumab Vedotin
- Where
- 83 sites in United States, Brazil and 5 more
- Volunteers
- 150 people
- Sponsor
- AbbVie
Non-small Cell Lung Cancer (NSCLC)
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without…
- Trial name
- TROPION-Lung17 (NCT07291037)
- Testing
- Datopotamab deruxtecan (Dato-DXd), Docetaxel
- Where
- 206 sites in United States, Australia and 19 more
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
This study is a single institution Phase II single arm trial to assess the efficacy of the combination of pevonedistat plus docetaxel in patients with previously treated advanced NSCLC (non-small cell lung cancer).
- Trial name
- NCT03228186
- Testing
- Pevonedistat, Docetaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan Rogel Cancer Center
Non Small Cell Lung Cancer
Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients
This 2 step study aims to establish a tolerable dose level and regimen of RAD001 in patients with advanced NCLC not previously treated with systemic therapy.
- Trial name
- NCT00457119
- Testing
- RAD001
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 69 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study
The objective of this study is to investigate the safety, tolerability, and antitumor activity of novel combination therapies administered in participants with advanced EGFRm NSCLC.
- Trial name
- NCT03381274
- Testing
- Oleclumab, Osimertinib, AZD4635
- Where
- 13 sites in United States, South Korea and 1 more
- Volunteers
- 43 people
- Sponsor
- MedImmune LLC